Clinical Trial · NCT06287411

Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies

Overview

This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards.

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase

N/A

Contacts

Xiao Chen, Ph.D (Principal Investigator)

xiaochen229@foxmail.com

+8615922970174

ClinicalTrials.gov

NCT06287411

Drug / Compound

Isotope(s):
Target(s):